Top High-Yield Healthcare Stocks to Consider
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Should l Buy PFE?
Source: Fool
- Pfizer's Current Status: Pfizer (PFE) has seen its annual revenue decline from over $100 billion in 2022 to below $60 billion due to reduced demand for its Comirnaty vaccine and Paxlovid treatment, resulting in its stock price dropping to less than half of its late-2021 peak, currently priced at $26.80 with a market cap of $152 billion and a dividend yield of 6.42%.
- Dentsply Sirona's Growth Potential: Dentsply Sirona (XRAY) offers a dividend yield slightly above 5%, and while it may not increase its annual payout every year, its dividend payments have more than doubled over the past decade, indicating stability and long-term growth potential in the dental supplies market, with a current stock price of $60.59.
- Bristol Myers Squibb's Profitability: Bristol Myers Squibb (BMY) has not seen net growth in its stock price over the past decade, yet it remains profitable with blockbuster drugs like Eliquis and Opdivo, providing steady cash flow, and its dividend yield stands at 4.11%, having been raised for 17 consecutive years, showcasing financial stability.
- Investment Opportunity Analysis: Despite short-term challenges faced by Pfizer and Bristol Myers Squibb, their high dividend yields and potential for new drug developments make these stocks attractive within the healthcare sector, especially during market downturns, allowing investors to capitalize on these undervalued stocks for long-term gains.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.770
Low
24.00
Averages
28.56
High
35.00
Current: 27.770
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer to Close South San Francisco Research Site
- Research Site Closure: Pfizer is set to close its South San Francisco research site and office by the end of April, indicating a significant pullback from the Bay Area's biotech sector, which could impact its market position in the region.
- Employee Transition: The company laid off 52 employees at this location, and while the exact number of employees at 181 Oyster Point Blvd. is unclear, all designated staff will transition to remote roles, reflecting a reassessment of office space utilization.
- Market Implications: This decision may suggest that the New York-based pharmaceutical giant is ending its presence in the Bay Area, indicating a potential decline in confidence in the local biotech market, which could affect future investments and partnerships.
- Continued California Operations: Despite the closure of the South San Francisco office, Pfizer maintains a strong presence in California, including facilities in San Diego, demonstrating the company's ongoing commitment to the state's market potential.
See More
FDA Poised to Allow Pharmacies to Sell Injectable Peptides
- Policy Shift Outlook: The FDA is likely to permit compounding pharmacies to sell injectable peptides again, a move that would be a victory for HHS Secretary Robert F. Kennedy Jr., despite opposition from many senior FDA officials regarding the safety of these products.
- Safety Risk Alerts: The FDA's updated list of banned peptides includes cesium chloride and chloral hydrate, with the former linked to irregular heartbeat and the latter associated with dosing errors and oversedation, highlighting significant safety concerns surrounding these substances.
- Regulatory Review Meeting: The FDA plans to schedule a meeting of its Pharmacy Compounding Advisory Committee to discuss medical evidence for the peptides and vote on whether to allow pharmacies to resume production, indicating a serious regulatory focus on product safety.
- Market Condition Analysis: Scott Brunner, CEO of the Alliance for Pharmacy Compounding, expressed concerns that consumers are likely purchasing unproven illicit products or research-grade items, as there are no pharmaceutical-grade versions available from FDA-registered manufacturers, illustrating the chaotic state of the market and lack of effective oversight.
See More
Trump's Drug Pricing Policy Affects European Market Launches
- Launch Decline: According to GlobalData, the number of pharmaceutical launches in Europe has decreased by 35% in the first ten months following the implementation of the International Reference Pricing policy, indicating that Trump's Most Favored Nation pricing policy may lead drugmakers to delay or withdraw products, thereby impacting market competitiveness.
- Increased Withdrawals: In the ten months following Trump's executive order, the number of brands with at least one pack withdrawn from the European market rose by 43%, suggesting that drugmakers may face a dilemma between maintaining access in lower-priced EU markets and ensuring U.S. pricing integrity.
- Policy Impact Assessment: While other factors could contribute to changes in drug launches and withdrawals, GlobalData notes that this trend may serve as an early signal of the impact that the introduction of International Reference Pricing in the U.S. may have on European markets, raising concerns about patient access and affordability.
- Case Study: For instance, Amgen recently withdrew its cholesterol therapy Repatha from the Danish market, reflecting the strategic considerations drugmakers must navigate in response to pricing policies, which could influence their market positioning in Europe.
See More
Analysis of DVY ETF's 52-Week Price Fluctuations
- Price Range Analysis: The DVY ETF has a 52-week low of $115.94 and a high of $158.915, with the latest trade at $150.71, indicating relative stability in the current market that may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the fund's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs experiencing significant inflows or outflows can provide investors with critical information regarding market sentiment and potential investment opportunities.
See More
Pharma Stocks Pfizer and GSK Provide Safe Investment Options Amid Market Uncertainty: Charts
Pharmaceutical Stocks in Focus: Investors are increasingly interested in pharmaceutical stocks as a stable investment option amid market uncertainty.
Market Volatility Impact: The sector is gaining attention due to its steady demand and resilient earnings, which are less affected by economic fluctuations.
See More
Eli Lilly's AI Investment: Implications for Its Stock Performance.
Eli Lilly's AI Integration: Eli Lilly is positioning itself as a leader in the healthcare industry's integration of artificial intelligence, indicating it has been proactive in this area.
Industry Response: The healthcare sector is currently working to adopt AI technologies, highlighting a broader trend towards innovation in medical practices.
See More
Pfizer to Close South San Francisco Research Site
- Research Site Closure: Pfizer is set to close its South San Francisco research site and office by the end of April, indicating a significant pullback from the Bay Area's biotech sector, which could impact its market position in the region.
- Employee Transition: The company laid off 52 employees at this location, and while the exact number of employees at 181 Oyster Point Blvd. is unclear, all designated staff will transition to remote roles, reflecting a reassessment of office space utilization.
- Market Implications: This decision may suggest that the New York-based pharmaceutical giant is ending its presence in the Bay Area, indicating a potential decline in confidence in the local biotech market, which could affect future investments and partnerships.
- Continued California Operations: Despite the closure of the South San Francisco office, Pfizer maintains a strong presence in California, including facilities in San Diego, demonstrating the company's ongoing commitment to the state's market potential.
See More
FDA Poised to Allow Pharmacies to Sell Injectable Peptides
- Policy Shift Outlook: The FDA is likely to permit compounding pharmacies to sell injectable peptides again, a move that would be a victory for HHS Secretary Robert F. Kennedy Jr., despite opposition from many senior FDA officials regarding the safety of these products.
- Safety Risk Alerts: The FDA's updated list of banned peptides includes cesium chloride and chloral hydrate, with the former linked to irregular heartbeat and the latter associated with dosing errors and oversedation, highlighting significant safety concerns surrounding these substances.
- Regulatory Review Meeting: The FDA plans to schedule a meeting of its Pharmacy Compounding Advisory Committee to discuss medical evidence for the peptides and vote on whether to allow pharmacies to resume production, indicating a serious regulatory focus on product safety.
- Market Condition Analysis: Scott Brunner, CEO of the Alliance for Pharmacy Compounding, expressed concerns that consumers are likely purchasing unproven illicit products or research-grade items, as there are no pharmaceutical-grade versions available from FDA-registered manufacturers, illustrating the chaotic state of the market and lack of effective oversight.
See More
Trump's Drug Pricing Policy Affects European Market Launches
- Launch Decline: According to GlobalData, the number of pharmaceutical launches in Europe has decreased by 35% in the first ten months following the implementation of the International Reference Pricing policy, indicating that Trump's Most Favored Nation pricing policy may lead drugmakers to delay or withdraw products, thereby impacting market competitiveness.
- Increased Withdrawals: In the ten months following Trump's executive order, the number of brands with at least one pack withdrawn from the European market rose by 43%, suggesting that drugmakers may face a dilemma between maintaining access in lower-priced EU markets and ensuring U.S. pricing integrity.
- Policy Impact Assessment: While other factors could contribute to changes in drug launches and withdrawals, GlobalData notes that this trend may serve as an early signal of the impact that the introduction of International Reference Pricing in the U.S. may have on European markets, raising concerns about patient access and affordability.
- Case Study: For instance, Amgen recently withdrew its cholesterol therapy Repatha from the Danish market, reflecting the strategic considerations drugmakers must navigate in response to pricing policies, which could influence their market positioning in Europe.
See More
Analysis of DVY ETF's 52-Week Price Fluctuations
- Price Range Analysis: The DVY ETF has a 52-week low of $115.94 and a high of $158.915, with the latest trade at $150.71, indicating relative stability in the current market that may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the fund's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs experiencing significant inflows or outflows can provide investors with critical information regarding market sentiment and potential investment opportunities.
See More
Pharma Stocks Pfizer and GSK Provide Safe Investment Options Amid Market Uncertainty: Charts
Pharmaceutical Stocks in Focus: Investors are increasingly interested in pharmaceutical stocks as a stable investment option amid market uncertainty.
Market Volatility Impact: The sector is gaining attention due to its steady demand and resilient earnings, which are less affected by economic fluctuations.
See More
Eli Lilly's AI Investment: Implications for Its Stock Performance.
Eli Lilly's AI Integration: Eli Lilly is positioning itself as a leader in the healthcare industry's integration of artificial intelligence, indicating it has been proactive in this area.
Industry Response: The healthcare sector is currently working to adopt AI technologies, highlighting a broader trend towards innovation in medical practices.
See More
